EFFECTIVENESS OF SUBCUTANEOUS ALLERGEN-SPECIFIC IMMUNOTHERAPY WITH TREE POLLEN ALLERGEN EXTRACT ADSORBED ON CALCIUM PHOSPHATE IN CHILDREN WITH ALLERGIC RHINOCONJUNCTIVITIS: RESULTS OF A 2 YEAR-LONG OBSERVATION

The study was aimed at evaluating effectiveness and safety of subcutaneous allergen-specific immunotherapy (scASIT) with tree pollen allergen extract adsorbed on calcium phosphate at allergic rhinoconjunctivitis in children. Patients and methods: open-label prospective study of 50 children and adolescents (5-17 years of age) with allergic rhinoconjunctivitis caused by high sensitivity to tree pollen allergens. The first group involved the patients undergoing scASIT for 2 years 6 months (n = 23), the control group – the patients (n = 27) not undergoing any specific immunotherapy. Results: scASIT was accompanied by a statistically significant (in comparison with the control group) reduction in intensity of rhinoconjunctivitis symptoms (6.1 ± 3.1; 11.8 ± 4.5; p = 0.00002), reduction in the use of symptomatic drugs (1.0 ± 0.4; 1.8 ± 0.3; p = 0.000004) and improvement of quality of all spheres of children’s life – physical (p = 0.001), social (p = 0.04), emotional (p = 0.001) and role functioning (p = 0.03). Systemic side reactions were not observed in the patients. Local reactions were observed in 23% of all allergen injections. Conclusions: the authors established high effectiveness and safety of scASIT with tree pollen allergen extract adsorbed on calcium phosphate suspension at allergic rhinoconjunctivitis in children.

1. Dahi R., Andersen P. S., Chivato T. National prevalence of respiratory allergic disorders. Respir. Med. 2004; 98: 398–403.

2. Bauchau V., Durham S. R. Prevalence and rate of diagnosis of allergic rhinitis in Europe. Eur. Respir. J. 2004; 24: 758–764.

3. Bousquet J., Bullinger M., Fayol C. et al. Assessment of quality of life in patients with perennial allergic rhinitis with the French version of the SF-36 Health Station Questionnaire. J. Allergy Clin. Immunol. 1994; 94: 182–188.

4. Leynaert B., Neukirch C., Liard R. et al. Quality of life in allergic rhinitis and asthma: A population-based study of young adults. J. Respir. Crit Care Med. 2000; 162: 1391–1396.

5. Storms W. W. Pharmacologic approaches to daytime and nighttime symptoms of allergic rhinitis. J. Allergy Clin. Immunol. 2004; 114 (Suppl.): 146–S153.

6. Stuck B. A., Czaikowski J., Hagner A. E. et al. Changes in daytime sleepiness, quality of life and objective sleep patterns in seasonal allergic rhinitis: A controlled clinical trial. J. Allergy Clin. Immunol. 2004; 113: 663–668.

7. Marshall P. S., Colon E. A. Effect of allergy season on mood and cognitive function. Ann. Allergy. 1993; 71: 251–258.

8. Gushchin I. S., Kurbacheva O. M. Allergiya i allergenspetsificheskaya immunoterapiya [Allergy and Allergenspecific Immunotherapy]. Moscow, 2010. 227 p.

9. Allergiya u detei: ot teorii — k praktike. Pod red. L.S. Namazovoi-Baranovoi. Seriya «Sovremennaya pediatriya: ot teorii — k praktike» [Allergy in Children: from Theory to Practice. Edited by L.S. Namazova-Baranova. Edition “Current Pediatrics: from Theory to Practice”]. Moscow, 2011. 668 p.

10. Malling H.J. Allergen immunotherapy efficacy in rhinitis and asthma. Allergy Clin. Immunol Int. J. World Allergy Org. 2004; 16 (3): 92–95.

11. Kurbacheva O. M. Rossiiskii allergologicheskii zhurnal = Russian allergological journal. 2004; 2: 32–54.

12. Moller C., Dreborg S., Ferdousi H. A. et al. Pollen immunotherapy reduces the development of asthma in children with seasonal rhinoconjunctivitis (the PAT-stady). J. Allergy Clin. Immunol. 2002; 109: 251–256.

13. Kumar P., Kamboj S., Rao P. et al. The cost of care and quality of life in patients with allergic rhinitis on allergen immunotherapy. J. Allergy Clin. Immun. Intern. 1997; 9 (5): 133–135.

14. Yilmaz M., Bingol G., Altindas D. et al. Effect of SIT on quality of life. Allergy. 2000; 55: 302–309.

15. Standards for practical allergen-specific immunotherapy. Allergy. 2006; 61 (Suppl. 82): 1–20.

16. Botey J., Cadahia A., Cobo R. et al. Tolerancia de la immunoterapia especifica con extractos alergenicos adsorbidos sobre fostato de calico. Rev. Esp. Alergolo Immunol. Clin. 1997; 12: 45–50.

17. Fadel R., Andre C., Bellanger M. et al. Tolerans, compliance et efficacite de immunotherapia specifique par des extraits allergeniques aqueus ou adsorbes sur phosphate de calcium. Etude retrospective. Rev. Fr. Allergol. 1998; 38: 41–49.

18. Kurbacheva O. M., Pavlova K. S., Il'ina N. I. et al. Rossiiskii allergologicheskii zhurnal = Russian allergological journal. 2009; 3: 27–31.

19. Mokronosova M. A., Korovkina E. S. Rossiiskii allergologicheskii zhurnal = Russian allergological journal. 2010; 4: 79–84.

20. Shakhova N. V., Gordeev V. V., Kharchenko S. S. et al. Rossiiskii allergologicheskii zhurnal = Russian allergological journal. 2011; 6: 79–84.

21. Shakhova N. V., Gordeev V. V., Tokarev V. P. et al. Mat' i ditya v Kuzbasse = Mother and child in Kuzbass. 2012; 3 (50): 37–41.

22. Shakhova N. V., Gordeev V. V., Tokarev V. P. et al. Rossiiskii allergologicheskii zhurnal = Russian allergological journal. 2012; 6: 44–48.

23. Shakhova N. V., Gordeev V. V., Lobanov Yu. F. et al. Mat' i ditya v Kuzbasse = Mother and child in Kuzbass. 2013; 1 (52): 50–54.

24. Wallner M., Briza P., Thalhamer J. Specific in pollen allergy. Curr. Opin. Mol. Ther. 2007; 9 (2): 160–167.

25. Calderon M., Mosges R., Helmich M. et al. Towards evidence — based in specific grass pollen immunotherapy. Allergy. 2010; 65: 420–434.